INTRODUCTION
Androgenetic alopecia (AGA) is the most common cause of hair loss among males [1] .
It is characterized by progressive thinning of the scalp hairs, defined by various patterns [2] , which can start at any age after puberty and is potentially reversible. Even if from a medical point of view, AGA is considered a relatively mild condition; however, people suffering from this condition consider AGA a serious condition that impacts their selfesteem, well-being, social relationships, and confidence.
The main factors underling hair loss in AGA are genetic predisposition and increased sensitivity of the hair follicles to androgens [3] . AGA is often precipitated and exacerbated by conditions that can induce telogen effluvium, including drugs, acute stressors, and weight loss [4] . However, in recent years it has been shown that other factors, such as microinflammation [5] , decreased microcirculation [6] , and aging [7] , can cause hair loss in AGA. These changes contribute to shifting the normal balance of the hair cycle leading to a shortening of the anagen phase.
The major components of balding in AGA are frontotemporal recession and loss of hair over the vertex. Hairs become shorter and finer, and finally complete hair loss occurs except at the lateral and posterior margins of scalp, where hair is retained.
Histologically, in AGA large terminal follicles diminish in size during hair cycles, and the resulting miniaturized follicle eventually produces a microscopic hair. Testosterone is necessary for miniaturization, and 5-alphareductase inhibitors, which block the conversion of testosterone to its more active form dihydrotestosterone (DHT), delay the progression of AGA [8] . Recently, Garza and coworkers [9] Cosprophar AG, which has filed a patent (CH 703 390 B1) [10] . signed by the subject prior to participating in the study.
MATERIALS AND METHODS

Subjects and Study Design
Healthy male volunteers suffering from alopecia grade II to IV according to the HamiltonNorwood scale [11] (Fig. 1) were enrolled in the study. Subjects were enrolled in the study by a certified dermatologist if they fulfilled the inclusion and exclusion criteria laid down in the study design (Table 1) were applicable.
Clinical examination was carried out in order to evaluate the degree and pattern of hair loss, and hair (length, diameter, and breakage) and scalp (inflammation, erythema and, scaling) conditions. Active and placebo treatments were then allocated by means of the Efron's biased coin algorithm using PASS 11 (version 11.0.8 for Windows; PASS, LLC., Kaysville, UT, USA). The tested and the placebo products were used for 4 months according to the following procedure: apply one vial (5 mL) of the product on clean and dry scalp, line by line, concentrating on the areas where thinning is more evident; massage gently to aid penetration; apply every day for 5 consecutive days, stop the treatment for 2 days and then continue the application.
Tested Product
The tested product is a commercially available cosmetic lotion named Crescina Ò HFSC. The ingredients of the tested product and placebo are listed in Table 2 .
Phototricogram
A transitional area of hair loss between normal hair and the balding area of 1.8 cm 2 was defined using a stencil template and chosen for clipping. The clipped hairs within the target area were dyed for gray or fair hairs with a commercially available solution (RefectoCil Ò , GW Cosmetics GmbH, Leopoldsdorf, Germany)
in order to enhance their contrast. Thereafter, the dyed hairs were cleansed using an alcoholic solution and digital images were taken while the area was still wet with a digital close-up camera. Images were taken at day 0, immediately after clipping, and 2 days after clipping. These two photographs were then examined by a software system that is able to recognize individual hair fibers in the photographs. By comparing the two photographs, the computer can determine which hairs are growing (anagen hairs) and 
Pull Test
Gentle traction was exerted on a cluster of hairs (approximately 60 hairs) on at least three different areas of the scalp, and the number of extracted hairs was counted. Normally, less than three telogen-phase hairs should come out with each pull [12] . If at least three hairs were obtained with each pull or if more than ten hairs total were obtained, the pull test was considered positive and suggestive of telogen effluvium.
Global Photographic Assessment
Patients were asked to maintain the same hair style, color, and length throughout the study.
Standardized global photographs of the frontal/ parietal region were taken using a digital camera equipped with a macro lens.
Statistical Analysis
An intention to treat statistical analysis was performed using NCSS 
RESULTS
Forty-six healthy male volunteers (Table 3) suffering from alopecia grade II to IV were enrolled in the study.
Anagen
The results of anagen hair rates (as %) at baseline (T0), 2 (T2), and 4 (T4) months are reported in Table 4 and Fig. 2 was also seen in the placebo group (65.0 ± 5.2%). The variation versus T0 (Fig. 3) of the anagen hair rate in the active product group was ?6.8 and ?10.7% after 2 and 4 months, respectively; whereas an improvement of ?2.2% was seen in the placebo group only at 4 months. Statistical analysis of the mean anagen rate in the active group showed a time-dependent statistically significant improvement (P\0.001); whereas in the placebo group, time was a source of variation only at 4 months (P = 0.004). Analysis of the mean anagen rate between the active group compared to the placebo group was also statistically significant (P\0.001). The improvement of anagen rate in the active group was observed in 95.7% (at T2) and 100% (at T4) of the subjects participating in the trial; whereas in the placebo group it was seen in 56.5% (at T2) and 69.6% (at T4).
Pull Test
The results of pull testing at baseline, 2, and 4 months are reported in Table 5 and Fig. 4 . Baseline mean pulled hairs in the pull test was similar between the active (9.2 ± 1.3) and placebo (9.1 ± 1.8) groups, which was not statistically significant (P[0.05). At the 2 months follow-up, only the active product group demonstrated a statistically significant improvement of 29.6% of hair resistance to traction (6.4 ± 1.8); whereas in the placebo (8.3 ± 2.1) group no changes were observed. At 4 months, the active product group 16.6% was also seen in the placebo group (7.6 ± 1.9). Statistical analysis of the mean anagen rate in the active group showed a timedependent statistically significant improvement (P\0.001); whereas in the placebo group, time was a source of variation only at 4 months (P = 0.044). Analysis of the hair fall in the hair pull test between the active group compared to the placebo group was also statistically significant (P\0.01 and P\0.001 at T2 and T4, respectively). The improvement of hair resistance to traction in the active group was observed in 89.5% (at T2) and 100% (at T4) of the subjects participating in the trial; whereas in the placebo group it was seen in 52.6% (at T2) and
78.9% (at T4).
Global Photographic Assessment Figure 5 shows the macroscopic effect of the product on hair growth. An increase in hair growth was seen in the frontal and parietal area (vertex) of the scalp.
DISCUSSION
Androgenetic alopecia is the most common cause of hair loss among males and has a psychosociologic impact on the well-being of the subject [1] . The pharmacologic treatment of AGA is expensive, requires lifelong treatment, and may have side effects. Subjects are also reluctant/intimidated to use drugs for a nonpathologic condition; however, use of cosmetics is more acceptable. A large number of cosmetics claiming to be effective in the coadjuvant treatment of AGA are sold on the market, but some lack proof of effect, relying only on the effects of the raw materials. Contrary to this approach, new cosmetic regulations [13] require manufactures to demonstrate product efficacy in order to protect subjects from misleading claims. 
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